Predace Injection(Methylprednisolone)

• Composition :
  Each vial contains: Methylprednisolone Sodium Succinate (MPPS) USP (Sterile) equivalent to Methylprednisolone 40 mg.
• Indications :
  Allergic states: Angioneurotic oedema Anaphylaxis Dermatologic diseases: Severe erythema multiforme (Stevens-Johnson syndrome). Gastrointestinal diseases: Crohn's disease Ulcerative colitis. Neurological disorders: Acute exacerbations of multiple sclerosis superimposed on a relapsing-remitting background. Secondary cerebral oedema caused by cerebal tumour Respiratory diseases: Aspiration of gastric contents Fulminat or disseminated pulmonary tuberculosis (with appropriate anti-tuberculosis chemotherapy), severe COVID 19. Miscellaneous: T.B.C. meningitis (with appropriate anti-tuberculosis chemotherapy) Transplantation.
• Pharmacodynamics :
  Methylprednisolone is a potent antiinflammatory steroid. The anti-inflammatory activity of MPPS lies in its ability to induce synthesis of lipocortin that blocks activation of phospholipase A at the site of cell damage. As a consequence, conversion of cell membrane-derived phospholipids into arachidonic acid is impaired. In inflammation, arachidonic acid gets converted to multiple potent mediators of inflammation, including the prostaglandins and leukotrienes by the cyclo-oxygenase and lipoxygenase pathways, respectively.
• Dosage and administration :
  Predace Injection-40 may be administered by IV or IM routes of injection, or by IV infusion. Adults: Methylprednisolone is administered 30 mg/kg intravenously over at least 30 minutes. This dose may be repeated every 4 to 6 hours for 48 hours. Children: Initial doses is 0.11 to 1.6 mg/kg/day in three or four divided doses (3.2 to 48 mg/m2 bsa/day).
• Contraindications :
  In systemic fungal infections and patients with known hypersensitivity to the product and its constituents for intrathecal administration. Intramuscular corticosteroid preparations are contraindicated for idiopathic thrombocytopenic purpura. Formulations preserved with benzyl alcohol are contraindicated for use in premature infants.
• Precautions and warnings :
  Few reports of cardiac arrhythmias and/or circulatory collapse and/or cardiac arrest associated with the rapid IV administration of larger doses of MPSS injection. Should be used cautiously in patients with ocular herpes simplex because of possible corneal perforation, active or latent peptic ulcer, renal insufficiency, hypertension, osteoporosis, or myasthenia gravis. An acute myopathy has been described with the use of high doses of corticosteroids, most often occurring in patients with disorders of neuromuscular transmission (eg, myasthenia gravis), or in patients receiving concomitant therapy with neuromuscular blocking drugs (eg, pancuronium).
• Use in pregnancy, lactation & pediatrics :
  Pregnancy category C: The use of corticosteroids in general during pregnancy involves balancing the clinical benefit against the possible risks. Potential for serious adverse reactions in nursing infants from corticosteroids have been observed, a decision should be made whether to continue nursing, or discontinue the drug, taking into account the importance of the drug to the mother. Corticosteroids cause growth retardation in infancy, childhood and adolescence. Treatment should be limited to the minimum dosage for the shortest possible time
• Drug interactions :
  Convulsions have been reported with concurrent use of methylprednisolone and cyclosporin. Hepatic microsomal enzyme inducing drugs such as phenobarbital, phenytoin and rifampin may increase the clearance of methylprednisolone and may require increases in methylprednisolone dose to achieve the desired response. Drug such as ketoconazole may inhibit the metabolism of methylprednisolone and thus decrease its clearance. Aspirin should be used cautiously in conjunction with corticosteroids in patients suffering from hypoprothrombinemia.
• Adverse reactions :
  Electrolyte disturbances, muscle weakness, pathologic fracture of long bones, osteoporosis, peptic ulcer, pancreatitis, ulcerative esophagitis. Impaired wound healing, facial burning or tingling, cutaneous, subcutaneous atrophy, dry scaly skin. Increased intracranial pressure, Suppression of growth in children, menstrual irregularities, decreased carbohydrate tolerance, manifestations of latent diabetes mellitus. Increased intraocular pressure. Masking of infections, activation of latent infections, opportunistic infections.
• Therapy Area :
  Corticosteroids